• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Senior Cuts?





I can only hope it was those morons and a**holes that came from SDI. I know the acquisition has not been approved yet by the FTC, but hopefully some type of pre-emptive move was made.

Here is the list in case you need help identifying the SDI idiot troop:

AD
JR
SP
DA
BD
 




IMS will be out of business in less than 5 years

Their data collection was never accurate.

Big pharma has begun dropping them.
Glaxo dropped them already.
JNJ next

and several mid and small companies are slated to not renew contracts.
 












TPG and the IMS break-up

TPG is quite upset with the investment bankers that packaged IMS and sold it to them. The investment will soon be worth zero and lawsuits should be flying.

Who was the fool that bought into this in the first place?